Patients requiring admission to the hospital due to a moderate and severe COVID-19infection may differ in their ability to respond to viral infection and to eliminateviral load.Several comorbidities and interventions like antivirotic or antiinflammatory treatmentmay also modify expected patients response and decrease of viral load.In this observational study, evolution of selected inflammatory markers, indicators ofseverity of infection and patient characteristics will be followed and recorded inhospitalized patients with COVID-19.
In this pilot study, 30 consecutive COVID-19 patients requiring admission to the hospital
due to a moderate and severe COVID-19 infection will be included into an observational
study.
Following parameters will be recorded: age, sex, weight, height, comorbidities, smoking
habit,spiritus and drug intake history, length of COVID-19 symptoms, clinical and
laboratory parameters, the use of different COVID-19 intervention (remdesivir,
convalescent plasma, monoclonal antibodies, corticosteroids, tocilizumab and other
medication), used initial and maximal organ support during the stay and outcome of the
stay in the hospital and 28th and 90th day, laboratory markers of severity of infection -
serum and tracheal aspirate (in ventilated patients) levels of nucleocapsid
antigen,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) viremia and quantity
in tracheal aspirates (in ventilated patients), makers of inflammatory response (C-
reactive proteins, Interleukin 6, procalcitonin, ferritin) and selected other biochemical
values (blood count, D-dimers, flow cytometry).
Inclusion Criteria:
- SARS CoV2 positive test within last 14 day
- bilateral infiltrates on chest X.ray or CT
- need for oxygen to keep pulse oximetry saturation above 92% or other respiratory
support measures (HFNO, non-invasive ventilation or invasive ventilation)
Exclusion Criteria:
- known history of intersticial lung disease
- known history of congestive heart failure
University Hospital Hradec Kralove
Hradec Kralove, Czechia
Investigator: Pavel Dostal, MD, PhD
Contact: 00420495832266
pavel.dostal@fnhk.cz
Pavel Dostál, MD, PhD
+420602455632
pavel.dostal@fnhk.cz
Vladimir Koblizek, MD, Ph.D.
+420723448641
vladimir.koblizek@fnhk.cz
Vladimir Palicka, MD, CSc., Study Chair
University Hospital Hradec Kralove